NTRK1 fusion
|
Neurofibrosarcoma
|
NTRK1 fusion
|
Neurofibrosarcoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Neurofibrosarcoma
|
NTRK3 fusion
|
Neurofibrosarcoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Neurofibrosarcoma
|
BRAF V600E
|
Neurofibrosarcoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
NF2 E108X
|
Neurofibrosarcoma
|
NF2 E108X
|
Neurofibrosarcoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
NF2 E108X
|
Neurofibrosarcoma
|
NF2 E108X
|
Neurofibrosarcoma
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
TSC2 A736V
|
Neurofibrosarcoma
|
TSC2 A736V
|
Neurofibrosarcoma
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
TSC2 A736V
|
Neurofibrosarcoma
|
TSC2 A736V
|
Neurofibrosarcoma
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
TJP1-ROS1 fusion + NF1 mutation
|
Neurofibrosarcoma
|
TJP1-ROS1 fusion + NF1 mutation
|
Neurofibrosarcoma
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
DR6MP + JHU395 Sensitive: D – Preclinical
|
DR6MP + JHU395 Sensitive: D – Preclinical
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
DR6MP Sensitive: D – Preclinical
|
DR6MP Sensitive: D – Preclinical
|
NF1 mutation
|
Neurofibrosarcoma
|
NF1 mutation
|
Neurofibrosarcoma
|
MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical
|
MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical
|
TP53 mutation
|
Neurofibrosarcoma
|
TP53 mutation
|
Neurofibrosarcoma
|
AZD1775 Sensitive: D – Preclinical
|
AZD1775 Sensitive: D – Preclinical
|